By skyforbes 
-
FDA decision on their glp weight loss oral pill will be coming in Q4. This can be a FDA decision on their glp weight loss oral pill will be coming in Q4. This can be a huge catalyst for a rerating of the stock. They are all but there.
-
They will present phase 3 trial data on Alzheimer's on December 3rd. They are apparently hiring for Alzheimer's roles to be ready to go. Who knows if that's an insider giveaway or them just trying to be ahead of the game.
-
Stock is beaten to pulp and these catalysts could drive a turnaround and re-rating of the stock, similar to how AMD was hated earlier this year and then a few catalysts changed the narrative. If these catalysts are positive, look for analysts to post high price targets and shower the stock with upgrades. You have to imagine the market for glp weight loss pills that shed significant pounds will be huge. And then Alzheimer's will be another significant population % for recurring revenue. My conservative price target for the stock is $70. This can really be their make or break moment after losing the race to LLY.